Anti-EGFR therapy on the retreatment clinical trials utilized cetuximab in all cases.
These trials utilized the Greene Climacteric Scale, in which patients self-rated their symptom severity (i.e. absent, mild, moderate, and severe).
Table 1 summarises the results from phase II trials utilizing bevacizumab in combination with chemotherapy, many of which are still preliminary.
Single blinded randomized clinical trial was utilized, in which 100 asthmatic patients were recruited from Al-Karama hospital and randomized into two groups; 1st group (50 patients, treated with ketotifen for 4 weeks) and 2nd group (50 patients treated with montelukast sodium for 4 weeks).
Data from myocardial I-MIBG scintigrams collected as part of a previously described trial were utilized in the present analyses [ 28].
A specific focus will be on the rationale behind ongoing clinical trials utilizing novel agents in concert with PI3K pathway inhibitors to reverse resistance in populations with and without gain of function alterations in this oncogenic signaling cascade.
Other large trials utilizing gastrointestinal decontamination in groups of critically ill patients have failed to demonstrate a decrease in mortality or intensive care days.
In this review, we focus on the different delivery strategies in cardiac regenerative therapy, as well as provide a brief overview of current clinical trials utilizing cell-based therapy in patients with ischemic heart disease.
Recent clinical trials utilizing recombinant IL-12 in the experimental treatment of human cancer illustrate the potential hazards of these approaches.
The second generation of perfluorocarbons appears highly promising for use in isovolemic hemodilution [ 12], but phase III trials utilizing perflubron – the latest perfluorocarbon – in the setting of cardiac surgery were recently terminated.
